Status:
TERMINATED
Blood Samples From Patients on a Clinical Trial to CINV During HSCT
Lead Sponsor:
OHSU Knight Cancer Institute
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Breast Cancer
Chronic Myeloproliferative Disorders
Eligibility:
All Genders
18-120 years
Brief Summary
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about nausea and vomiting caused by cancer treatment. PURPOSE: This laboratory study is lo...
Detailed Description
OBJECTIVES: Primary * To compare the amount of substance P in serum samples from patients with cancer treated with busulfan/cyclophosphamide or cyclophosphamide/total body irradiation conditioning r...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Previously collected serum samples from patients with cancer enrolled on the placebo arm of the pilot aprepitant study
- Patients treated with busulfan/cyclophosphamide or cyclophosphamide/total body irradiation conditioning regimens prior to undergoing allogeneic hematopoietic stem cell transplantation
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Exclusion
Key Trial Info
Start Date :
August 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00900068
Start Date
August 1 2008
End Date
October 1 2009
Last Update
May 9 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
OHSU Knight Cancer Institute
Portland, Oregon, United States, 97239-3098